PURPOSE: The aim of our study was to assess the feasibility and usefulness of 2-[(18)F]-fluoro-2-deoxy-D: -glucose positron emission tomography computed tomography ([(18)F]FDG-PET/CT) in patients affected by retroperitoneal fibrosis. MATERIALS AND METHODS: We retrospectively evaluated 25 patients studied in two centers: 18 underwent [(18)F]FDG-PET/CT as initial evaluation, three during follow-up, three during steroid therapy, and one to re-evaluate the disease. Among the group who underwent initial evaluation, ten underwent a second [(18)F]FDG-PET/CT after steroid therapy. RESULTS: [(18)F]FDG-PET/CT was positive in 18 patients and negative in seven. Among the ten patients who underwent a second study after steroid therapy, six showed complete metabolic response, three partial response, and one no significant maximum standardized uptake value (SUV(max)) reduction. CONCLUSION: Our preliminary results show that [(18)F]FDG-PET/CT is feasible and suitable for evaluating retroperitoneal fibrosis and is useful in assessing therapy response. Larger studies are desirable to confirm these findings and to determine the appropriate position of [(18)F]FDG-PET/CT in the diagnostic flow chart for this disease.
PURPOSE: The aim of our study was to assess the feasibility and usefulness of 2-[(18)F]-fluoro-2-deoxy-D: -glucose positron emission tomography computed tomography ([(18)F]FDG-PET/CT) in patients affected by retroperitoneal fibrosis. MATERIALS AND METHODS: We retrospectively evaluated 25 patients studied in two centers: 18 underwent [(18)F]FDG-PET/CT as initial evaluation, three during follow-up, three during steroid therapy, and one to re-evaluate the disease. Among the group who underwent initial evaluation, ten underwent a second [(18)F]FDG-PET/CT after steroid therapy. RESULTS: [(18)F]FDG-PET/CT was positive in 18 patients and negative in seven. Among the ten patients who underwent a second study after steroid therapy, six showed complete metabolic response, three partial response, and one no significant maximum standardized uptake value (SUV(max)) reduction. CONCLUSION: Our preliminary results show that [(18)F]FDG-PET/CT is feasible and suitable for evaluating retroperitoneal fibrosis and is useful in assessing therapy response. Larger studies are desirable to confirm these findings and to determine the appropriate position of [(18)F]FDG-PET/CT in the diagnostic flow chart for this disease.
Authors: E Maillart; L Lauerière; S Kassis; L Moulonguet-Doleris; J Prinseau; A Baglin; T Hanslik Journal: Rev Med Interne Date: 2006-06-21 Impact factor: 0.728
Authors: D Corradi; R Maestri; A Palmisano; S Bosio; P Greco; L Manenti; S Ferretti; R Cobelli; G Moroni; A P Dei Tos; C Buzio; A Vaglio Journal: Kidney Int Date: 2007-07-11 Impact factor: 10.612
Authors: Augusto Vaglio; Domenico Corradi; Lucio Manenti; Stefania Ferretti; Giovanni Garini; Carlo Buzio Journal: Am J Med Date: 2003-04-15 Impact factor: 4.965
Authors: Giorgio Treglia; Maria Vittoria Mattoli; Francesco Bertagna; Raffaele Giubbini; Alessandro Giordano Journal: Rheumatol Int Date: 2012-11-05 Impact factor: 2.631
Authors: Giorgio Treglia; Antonella Stefanelli; Maria Vittoria Mattoli; Lucia Leccisotti; Barbara Muoio; Francesco Bertagna Journal: Nucl Med Mol Imaging Date: 2012-11-17
Authors: Isidora T Grozdic Milojevic; Bogomir Milojevic; Dragana P Sobic-Saranovic; Vera M Artiko Journal: Rheumatol Int Date: 2017-08-24 Impact factor: 2.631